Admission to Trading / TVR (5973Z)
19 Marzo 2012 - 6:00AM
UK Regulatory
TIDMLSI
RNS Number : 5973Z
Lifeline Scientific, Inc
19 March 2012
19 March 2012
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Admission of shares and TVR
Lifeline Scientific, the medical technology company focused on
the worldwide commercialisation of its LifePort Kidney Transporter,
a product designed to address the global challenge of human donor
organ shortages, on 15 March 2012 transferred 427,132 common shares
of $0.01 each from Regulation S restricted stock to unrestricted
stock. Admission is expected to occur tomorrow.
Lifeline has 19,424,959 common shares in issue and each share
has the right to one vote. Therefore for the purposes of the FSA
Disclosure and Transparency Rules the total number of voting rights
in the Company is 19,424,959.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine whether they are
required to notify the Company of their interests in, or change to
their interests in, Lifeline Scientific, Inc. under the FSA's
Disclosure and Transparency Rules.
Following this transfer, 6,851,217 common shares remain subject
to Regulation S restrictions and are held in certificated form
only. These common shares subject to Regulation S restrictions are
traded under ISIN number USU529641008.
The remaining 12,573,742 common shares have had the Regulation S
restrictions lifted and are held in uncertificated form trading
under ISIN number US53223V1017.
Enquiries:
Lifeline Scientific, Inc. + 001 847 294 0300
David Kravitz, CEO
Seymour Pierce +44 (0)20 7107 8000
Sarah Jacobs / Mark Percy
(Corporate Finance)
David Banks (Corporate
Broking)
Financial Dynamics +44 (0)20 7831 3113
Ben Brewerton
About the LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is designed to provide improved
kidney preservation, evaluation and transport prior to
transplantation. LifePort provides a sealed, sterile, protected
environment where a medical solution is gently pumped through the
kidney at cold temperatures to minimize damage while the organ is
outside the body. LifePort is lightweight and portable, allowing
organs to be perfused from the time of recovery until transplant.
It is designed to travel unaccompanied by land or air, safely
transporting the kidneys across town or between countries. While
the kidney is being perfused, the LifePort records data on
temperature, flow rate, vascular resistance, and pressure every 10
seconds providing surgeons with additional data prior to
transplant.
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with European headquarters located in Brussels.
Its primary focus is the global commercialization of its FDA
cleared, CE marked, clinically validated, LifePort Kidney
Transporter and related consumables. LifePorts for preservation of
the liver, heart, lung and pancreas are in late stage pre-clinical
development along with new proprietary solutions and medical
accessories to help improve the preservation, evaluation, and
transport of organs for transplantation.
For further information please see
www.lifeline-scientific.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBKLFFLXFEBBL
Lifeline Sci. S (LSE:LSI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Lifeline Sci. S (LSE:LSI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024